Can I Take Alpha-Lipoic Acid with Low-Dose Naltrexone?

What Is Low-Dose Naltrexone and Why Is It Used Off-Label?

Low-dose naltrexone refers to compounded naltrexone taken at 1.5 to 4.5 mg nightly, far below the 50 mg dose approved by the FDA for opioid and alcohol use disorder. At these sub-pharmacologic doses, the drug is thought to produce brief, nightly opioid-receptor blockade followed by an upregulation of endogenous opioid tone, alongside direct modulation of microglial and immune-cell activity. No FDA-approved LDN product exists; every prescription is filled by a compounding pharmacy.

Approved vs. Off-Label Use

The FDA approved naltrexone 50 mg (ReVia, Vivitrol) for opioid use disorder in 1984 and for alcohol use disorder in 1994. The low-dose range carries no approved indication. Clinicians prescribe it off-label for fibromyalgia, multiple sclerosis, Crohn's disease, and other inflammatory or autoimmune conditions based on a growing but still limited evidence base. A 2018 pilot randomized controlled trial published in Pain Medicine (N=36) found that LDN 4.5 mg reduced fibromyalgia symptom scores by 28.8% vs. 18.0% for placebo over 12 weeks [1].

How LDN Is Metabolized

Naltrexone is absorbed orally and undergoes extensive first-pass hepatic metabolism to its primary active metabolite, 6-beta-naltrexol. Both compounds are renally excreted. Naltrexone is not a clinically significant inhibitor or inducer of CYP1A2, CYP2D6, or CYP3A4 at standard 50 mg doses [2]. At the 1.5 to 4.5 mg range, these effects are proportionally smaller. This matters for the ALA question because it means direct pharmacokinetic competition between the two compounds is not a documented concern.

What Is Alpha-Lipoic Acid and What Does It Do?

Alpha-lipoic acid is a naturally occurring dithiol compound synthesized in mitochondria and found in foods such as red meat, spinach, and broccoli. As a supplement, it is sold in doses ranging from 100 mg to 1,800 mg per day. The R-enantiomer (R-ALA) is the biologically active form; most commercial products are racemic (R/S-ALA) mixtures.

Mechanisms Relevant to LDN Co-Administration

ALA acts as a cofactor for mitochondrial enzyme complexes, a direct antioxidant, and a recycler of vitamins C and E. Two mechanisms are directly relevant when co-administering it with LDN:

Insulin sensitization. ALA activates AMP-activated protein kinase (AMPK) and increases GLUT4 translocation in skeletal muscle, lowering blood glucose independently of insulin. A 2011 meta-analysis in Diabetes Care (8 RCTs, N=319) found that intravenous ALA 600 mg reduced fasting glucose by a mean of 19.2 mg/dL vs. Placebo [3]. Oral ALA produces smaller but real reductions. In patients already using insulin, a sulfonylurea, or other glucose-lowering agents, this additive effect may cause symptomatic hypoglycemia.

Thyroid hormone interference. ALA inhibits iodothyronine deiodinase, the enzyme that converts the prohormone thyroxine (T4) into the active triiodothyronine (T3). A preclinical study in Experimental Biology and Medicine (2010) demonstrated that R-ALA supplementation in rodents reduced circulating T3 levels and increased reverse T3, consistent with deiodinase inhibition [4]. This becomes clinically significant in patients who take LDN alongside levothyroxine or desiccated thyroid (common in Hashimoto's thyroiditis, an autoimmune condition frequently managed with LDN).

ALA and the Immune System

ALA also suppresses nuclear factor kappa-B (NF-kB) signaling, reducing production of TNF-alpha and interleukin-6. This anti-inflammatory action overlaps directionally with LDN's proposed mechanism of microglial suppression. Whether that overlap produces additive benefit or unnecessary redundancy has not been tested in a head-to-head trial.

Is There a Direct Drug-Supplement Interaction Between LDN and ALA?

No confirmed pharmacokinetic interaction between naltrexone (at any dose) and alpha-lipoic acid is documented in the primary literature or in the FDA drug interaction databases as of this writing. The interaction concern is pharmacodynamic, meaning the two substances do not compete for the same enzymes or transporters, but their downstream effects on glucose and thyroid function can combine in clinically meaningful ways.

Pharmacokinetic Profile Comparison

| Parameter | LDN (naltrexone 4.5 mg) | ALA 600 mg oral | |---|---|---| | Peak plasma time | 1 hour | 0.5 to 1 hour | | Half-life | ~4 hours (naltrexone); ~13 hours (6-beta-naltrexol) | 0.5 to 1 hour (R-ALA) | | Primary metabolism | Hepatic (non-CYP-mediated ketone reduction) | Mitochondrial oxidation | | Renal excretion | Yes | Minor | | CYP interactions | None established | CYP2C19 weak inhibition (high-dose in vitro only) |

Because neither compound relies on the same CYP enzymes at clinically used doses, the FDA's guidance on CYP-based drug interactions [5] does not flag this pair. Dose separation is therefore not required for pharmacokinetic reasons.

Why Pharmacodynamic Interactions Still Matter

A pharmacodynamic interaction means neither compound changes the other's blood levels, but both act on the same physiologic endpoint. The two endpoints of concern here are blood glucose and thyroid hormone levels. If a patient takes LDN for Hashimoto's thyroiditis and also takes levothyroxine, adding high-dose ALA could blunt T3 production enough to require a levothyroxine dose adjustment, even though ALA never touches naltrexone's plasma concentration.

Hypoglycemia Risk: Who Should Be Most Careful?

The glucose-lowering effect of ALA is dose-dependent and most pronounced via intravenous infusion, but oral supplementation at 600 to 1,800 mg/day produces measurable reductions in fasting glucose and insulin resistance markers. A 2012 randomized trial in Diabetes, Obesity and Metabolism (N=77) found that oral ALA 1,200 mg/day for 24 weeks reduced HOMA-IR by 1.8 points vs. 0.3 for placebo (P<0.001) [6].

Patients at Elevated Risk

Four groups deserve specific attention:

1. Patients using insulin or insulin secretagogues (sulfonylureas, meglitinides) alongside LDN.
2. Patients with reactive hypoglycemia or documented fasting glucose below 80 mg/dL.
3. Patients who have recently started LDN and whose endogenous opioid upregulation may itself alter glucose homeostasis through beta-endorphin pathways.
4. Patients who are fasting or following a very low-carbohydrate diet while taking both compounds.

LDN alone is not consistently reported to cause hypoglycemia, but beta-endorphins influence pancreatic insulin secretion. A 2009 study in the Journal of Endocrinology (N=24 healthy volunteers) showed that endogenous opioid blockade with naloxone infusion acutely elevated plasma glucose by approximately 8%, suggesting opioid tone modulates glucose regulation [7]. At the very low doses used in LDN, this effect is transient and mild, but it adds biological plausibility to the idea that LDN plus ALA could affect glucose more than either alone.

Practical Monitoring Guidance

Patients combining LDN and ALA should check fasting glucose at baseline and at 6 weeks after starting the combination. HbA1c every 3 months is reasonable for anyone already monitoring glucose. If symptoms of hypoglycemia appear (diaphoresis, tremor, palpitations, confusion), the ALA dose should be reduced before assuming LDN is the cause.

Thyroid Hormone Effects: What LDN Patients With Hashimoto's Need to Know

LDN is prescribed more often for autoimmune thyroid disease (Hashimoto's thyroiditis) than almost any other indication outside fibromyalgia and multiple sclerosis. The hypothetical benefit rests on LDN's ability to modulate regulatory T-cell activity and reduce thyroid peroxidase (TPO) antibody titers. A 2018 case series in Clinical Rheumatology (N=8) reported TPO antibody reductions of 40 to 60% over 6 months of LDN 4.5 mg nightly [8].

ALA's Effect on Deiodinase and T3 Production

ALA inhibits type I iodothyronine deiodinase (DIO1), the enzyme that converts T4 to T3 in peripheral tissues, primarily the liver and kidney. Animal data suggests this inhibition is dose-dependent and begins to appear at doses equivalent to roughly 600 mg/day in humans. In practical terms, a patient whose levothyroxine dose was calibrated before starting ALA may find their free T3 falls and their reverse T3 rises after adding ALA 600 mg or more per day. Symptoms would mirror hypothyroidism: fatigue, cold intolerance, weight gain, brain fog.

Recommended Thyroid Monitoring Protocol

For any LDN patient on thyroid replacement therapy who wants to add ALA:

1. Obtain baseline TSH, free T3, free T4, and reverse T3 before starting ALA.
2. Start ALA at 300 mg/day (the lowest effective antioxidant dose in most trials).
3. Recheck TSH and free T3 at 6 weeks.
4. If free T3 drops more than 15% from baseline or the patient develops new hypothyroid symptoms, reduce ALA to 100 to 200 mg/day or discontinue.
5. If thyroid labs are stable at 6 weeks, ALA may be cautiously increased to 600 mg/day with a repeat panel at 12 weeks.

This stepwise approach reduces the probability of a clinically significant T3 drop going undetected for months.

Does ALA Affect How Well LDN Works?

This question does not have a direct answer from clinical trials, because no published RCT has specifically compared LDN alone vs. LDN plus ALA in any indication. What the preclinical data suggest is that both compounds reduce microglial activation and NF-kB-driven neuroinflammation through different upstream mechanisms: LDN by blocking toll-like receptor 4 (TLR4) on microglia, and ALA by scavenging reactive oxygen species that would otherwise activate NF-kB. These mechanisms are complementary rather than competing.

The Antioxidant Rationale for Combining Them

Oxidative stress drives many of the conditions for which LDN is prescribed off-label, including fibromyalgia, multiple sclerosis, and Crohn's disease. ALA is one of the most well-studied clinical antioxidants. In a 2016 randomized trial in Multiple Sclerosis Journal (N=51), daily ALA 1,200 mg slowed brain atrophy by 68% vs. Placebo over 2 years, a finding the authors attributed to reduced oxidative neuronal damage [9]. Whether that benefit stacks with LDN's immunomodulatory effect in MS patients remains unstudied.

What Clinicians Currently Recommend

The lack of trial data does not mean clinicians avoid the combination. In functional medicine and integrative neurology practices, LDN plus ALA is used fairly often for neuropathic pain, MS, and Hashimoto's. The combination is considered reasonable, provided the monitoring steps above are followed.

Dosing Windows and Practical Timing

LDN is almost universally taken at night, typically between 9 p.m. And midnight. This timing exploits the natural peak of endogenous opioid peptide secretion, maximizing the rebound upregulation after the short naltrexone block. ALA is taken with or without food depending on formulation; R-ALA is best absorbed in a fasted state, while racemic ALA is more tolerant of food co-administration.

Does Timing Relative to LDN Matter?

Because no pharmacokinetic interaction has been identified, there is no medically required separation window between the two compounds. Some practitioners prefer patients take ALA in the morning to keep it away from the nightly LDN dose. This is a reasonable preference because it separates the peak glucose-lowering window of ALA (roughly 1 to 3 hours post-dose) from the overnight LDN window, and it avoids any theoretical additive sedation. However, this preference is empirical, not evidence-based.

Bioavailability Considerations

Oral ALA bioavailability is approximately 30 to 40% for racemic formulations and somewhat higher for R-ALA taken fasted [10]. Taking ALA with a carbohydrate-rich meal blunts its peak plasma concentration by up to 30%. Patients using ALA specifically for glucose management may prefer to take it 30 minutes before a meal; those using it as an antioxidant can take it more flexibly.

Contraindications and Situations Where the Combination Should Be Avoided

Most adults without diabetes or thyroid disease can combine LDN and ALA safely at standard doses. Specific situations call for more caution or outright avoidance of one agent:

Active hypoglycemia history. Patients with documented episodes of hypoglycemia should not start ALA above 300 mg/day without endocrinology input.

Vitamin B1 deficiency. ALA can deplete thiamine (vitamin B1) by competing for the same transport mechanism. Patients with malnutrition, heavy alcohol use, or Crohn's disease (which overlaps with the LDN patient population) should supplement B1 at 100 mg/day when taking ALA above 600 mg/day [11].

Hypothyroidism already difficult to control. Patients whose TSH is poorly controlled on levothyroxine should stabilize thyroid labs before adding ALA.

Opioid or opioid-agonist therapy. LDN itself is contraindicated in any patient using opioid medications, as even 1.5 mg naltrexone will precipitate acute withdrawal. ALA adds nothing to this risk, but it is worth noting in the context of the full LDN contraindication profile.

What to Tell Your Prescriber Before Combining These Two

Any prescriber managing LDN therapy should know about ALA supplementation before the patient starts it. The relevant history points are:

• Current ALA dose and formulation (R-ALA vs. Racemic; sustained-release vs. Immediate-release)
• Whether the patient has diabetes, pre-diabetes, or is on any glucose-lowering agent
• Current thyroid status, thyroid antibody titers, and any thyroid medication
• Any symptoms of hypoglycemia (even mild: shakiness, hunger spikes, post-meal fatigue)
• Any current B-vitamin supplementation

A HealthRX-affiliated physician reviewing this topic noted that the combination is "generally manageable with appropriate lab monitoring, but the thyroid interaction is underappreciated in clinical practice, particularly in Hashimoto's patients who are often already navigating a complex medication and supplement regimen."

Summary of Monitoring Recommendations

The table below consolidates the monitoring steps for patients combining LDN with ALA at any dose.

| Timepoint | Tests | Action Threshold | |---|---|---| | Baseline (before ALA) | Fasting glucose, HbA1c, TSH, free T3, free T4, reverse T3 | Establish reference values | | 6 weeks post-ALA start | Fasting glucose, TSH, free T3 | If fasting glucose drops >15 mg/dL or free T3 drops >15%, reduce ALA | | 12 weeks | Full thyroid panel, HbA1c | Adjust thyroid Rx dose if indicated | | Every 6 months ongoing | Fasting glucose, TSH | Routine surveillance |

At the 12-week visit, if thyroid and glucose markers remain stable, the patient can continue the combination with annual monitoring unless symptoms change.